Investigate the Diagnostic Value and Possibilities of OCT in Non-Melanoma Skin Cancer.

NCT ID: NCT00390351

Last Updated: 2006-10-19

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 120 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2006-02-28
• Study Completion Date: 2008-07-31

Brief Summary

We will do systematic and functional assessment of non-melanoma skin cancer including precancerous lesions by OCT imaging and other diagnostic methods. The systematic assessment will be comparison of clinical diagnosis, histopathology, OCT images, spectrophotometry and high frequency ultrasound of non-melanoma skin cancer Functional exploration of non-melanoma skin cancer is done with Doppler-OCT and polarization-sensitive-OCT.

Detailed Description

Optimal management of skin malignancies relies on early and accurate diagnosis. The reference standard in skin cancer is biopsy and histopathological assessment from a clinical suspicious skin lesion. The clinical diagnosis of skin cancer has sensitivity ranging from 50% to 90 % and specificity around 70% to 80% depending on the population studied and the experience of the clinician.

A rapid, non-invasive technique that could be used for characterization of skin lesions prior to biopsy would be valuable. In some patients with multiple, recurrent skin tumours the need for numerous biopsies in the same area is problematic, both cosmetically and diagnostically, as the cancer can be hidden under scar tissue.

The biopsy has several weaknesses: The biopsy must be done exactly in the tumour, and it does not delineate the tumour borders. Biopsy from skin is in general easy, but there are problematic places such as the T-zone in the face, the eyelids and the ears. Notably these places are areas where most types of skin cancer exhibit aggressive, invasive growth and have a high recurrence rate.

OCT is a novel, non-invasive optical imaging technology. It can provide cross-sectional tomographic images of tissue pathology in situ and in real time, without the need for excision and processing of specimens, as in conventional histopathology. OCT uses harmless, infrared light to create high-resolution images of tissue. OCT provides cross-sectional images of structures below the tissue surface in analogy to histopathology. Hence OCT can function as an "optical biopsy" providing images of tissue structure on the micron scale. For example, OCT could be used where standard excisional biopsy is hazardous or impossible, and OCT could reduce sampling errors associated with excisional biopsy.

Conditions

Skin Neoplasms

Keywords

Optical coherence tomography

Study Design

• Observational Model Type: DEFINED_POPULATION
• Study Time Perspective: OTHER

Interventions

optical coherence tomography

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patients above the age of 18 years with primary non-melanoma skin cancer NMSC or precancerous lesions from the Dermatology Department, and the Plastic Surgery Department at Roskilde Hospital, and from office based dermatologist in Roskilde County. Patients will only be recruited after informed consent.

Exclusion Criteria

• Pregnancy.
• To avoid the potential bias of scar tissue in the OCT images we will not include OCT images from recurrent NMSC in this study.
• Patients will be excluded from the study if they are not able to give an informed consent. Staff from the Dermatology, Internal Medicine and Plastic Surgery Departments at RAS cannot be included in the phase I/phase 2 study.
• Gender: both
• Age limits: 18- no max

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Zealand University Hospital

OTHER

Sponsor Role: lead

Principal Investigators

Mette Mogensen, MD

Role: PRINCIPAL_INVESTIGATOR

Dept. of Dermatology, Roskilde Hospital

Gregor BE Jemec, MD, DMSc

Role: STUDY_DIRECTOR

Dept. of Dermatology, Roskilde Hospital

Locations

Roskilde Hospital

Roskilde, Roskilde, Denmark

Site Status: RECRUITING

Dept. of Dermatology, Copenhagen University

Dk-4000 Roskilde, , Denmark

Site Status: SUSPENDED

Countries

Denmark

Central Contacts

Mette Mogensen, MD

Role: CONTACT

Phone: +45 4732 2116

Email: rsmmog@ra.dk

Gregor BE Jemec, MD, DMSc

Role: CONTACT

Phone: +45 4732 2022

Email: rsgrj@ra.dk

Facility Contacts

Mette Mogensen, MD

Role: primary

Gregor BE Jemec, MD, DMSc

Role: backup

Other Identifiers

Grant # BIOPHOT 26-02-0020

Identifier Type: -

Identifier Source: secondary_id

oct-MM-2005

Identifier Type: -

Identifier Source: org_study_id